Walleye Capital
PTGX icon

Walleye Capital’s Protagonist Therapeutics PTGX Stock Holding History

Walleye Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,335
Closed -$4.74M – 5418
2024
Q3 		$4.74M Buy
+105,335
New +$4.26M 0.01% 1218
2024
Q2 		– Sell
-134,114
Closed -$3.88M – 5919
2024
Q1 		$3.88M Sell
134,114
-51,312
-28% -$1.4M 0.01% 1491
2023
Q4 		$4.25M Buy
185,426
+51,610
+39% +$903K 0.01% 1209
2023
Q3 		$2.23M Buy
133,816
+81,155
+154% +$1.57M 0.01% 1651
2023
Q2 		$1.45M Sell
52,661
-74,709
-59% -$1.87M 0.01% 1550
2023
Q1 		$2.93M Sell
127,370
-396,932
-76% -$6.67M 0.04% 512
2022
Q4 		$5.72M Buy
524,302
+421,359
+409% +$3.55M 0.1% 238
2022
Q3 		$868K Sell
102,943
-154,414
-60% -$1.46M 0.02% 1080
2022
Q2 		$2.04M Buy
257,357
+223,967
+671% +$2.71M 0.06% 361
2022
Q1 		$791K Sell
33,390
-64,608
-66% -$1.82M 0.02% 748
2021
Q4 		$3.35M Buy
97,998
+87,882
+869% +$2.78M 0.1% 207
2021
Q3 		$179 Buy
+10,116
New +$431K 0.01% 1214

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Walleye Capital's PTGX Position: Q4 2024 in Review

Walleye Capital sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 105,335 shares — an estimated $4.74M sold.

Walleye Capital first reported a position in PTGX in Q3 2021 and held it in 12 quarters. The position peaked at $5.72M in Q4 2022. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Walleye Capital reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 105,335 Protagonist Therapeutics shares in Q4 2024, an estimated $4.74M.
  • Walleye Capital first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 12 quarters.
  • Walleye Capital's Protagonist Therapeutics position peaked at $5.72M in Q4 2022.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.